Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind comparison of JT1801 versus darbepoetin alfa in maintenance treatment of anemia in Chinese adults with chronic kidney disease on hemodialysis
CTR20250947Phase 3Active
- Sponsor
- North China Pharmaceutical Jintan Biotechnology
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of JT-1801 in Uraemic Anaemia, sponsored by North China Pharmaceutical Jintan Biotechnology. Started Mar 2025; status: active.
02
Drugs
JT-1801
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on CTR20250947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250947.